Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

Condition(s) targeted: Breast Cancer

Intervention: allogeneic GM-CSF-secreting breast cancer vaccine (Biological); cyclophosphamide (Drug); doxorubicin hydrochloride (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: Sidney Kimmel Comprehensive Cancer Center

Official(s) and/or principal investigator(s):
Leisha A. Emens, MD, PhD, Principal Investigator, Affiliation: Sidney Kimmel Comprehensive Cancer Center

RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with cyclophosphamide and doxorubicin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide and doxorubicin when given with vaccine therapy in treating women with stage IV breast cancer.

Official title: A Phase I Vaccine Safety and Chemotherapy Dose-Finding Trial of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine Given in a Specifically Timed Sequence With Immunomodulatory Doses of Cyclophosphamide and Doxorubicin

Study design: Treatment, Open Label

Primary outcome:

Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by history and phys. exam. at 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination

Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by CBC w/ differential at days 7, 14, 21, and 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination

Toxicity of vaccine w/ & w/o cyclophosphamide+doxorubicin by comprehensive metabolic panel at day 7 and 28-42 days after each vaccination, 56-84 days after third vaccination, 6 months after first vaccination, and annually after first vaccination

Immune resp. of HER-2/neu by serum antibody titers, delayed hypersensitivity to HER-2/neu-derived peptides, and CD4+ T-cell resp. by ELISPOT at days 28-42 after each vaccination and days 56-84 after third vaccination

Immune responses by immunohistochemical analysis of vaccine site biopsies at days 3 and 7 after the first and third vaccinations

Secondary outcome: Time to disease progression by history and physical examination, computed tomography, bone scans, and tumor markers as appropriate at days 28-42 after third and fourth vaccinations and days 56-84 after third vaccination

Detailed description: OBJECTIVES:

Primary

- Determine the safety of vaccination comprising allogeneic sargramostim

(GM-CSF)-secreting breast cancer cells with or without immunomodulation using cyclophosphamide and doxorubicin in women with stage IV breast cancer.

- Determine the doses of cyclophosphamide and doxorubicin that maximize vaccine-induced

immunity, in terms of immune response to HER2/neu, in patients treated with these regimens.

- Compare in vivo immune response induced by these regimens, as measured by

immunohistochemical analysis of vaccine site biopsies from these patients, with responses seen in prior preclinical and clinical studies.

Secondary

- Determine the time to disease progression in patients treated with these regimens.

OUTLINE: This is a dose-finding study.

The first 6 patients receive 1 of 2 doses of vaccine comprising allogeneic sargramostim (GM-CSF)-secreting breast cancer cells intradermally (ID) on day 0. Subsequent patients

receive cyclophosphamide IV on day - 1, vaccine at the higher dose ID on day 0, and

doxorubicin IV on day 7. Treatment in all patients repeats every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease after the third course receive a fourth course of treatment at approximately 4 months after completion of the third course.

Cohorts of 2-3 patients receive a fixed dose of vaccine in combination with escalating doses of doxorubicin and cyclophosphamide. Doses of cyclophosphamide and doxorubicin are escalated until an optimal dose of combination chemotherapy with a fixed dose of vaccine is achieved.

Patients are followed at 1 month and 4 months after completion of study therapy and then annually thereafter.

PROJECTED ACCRUAL: A total of 6-60 patients will be accrued for this study.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.

Criteria:

DISEASE CHARACTERISTICS:

- Histologically confirmed adenocarcinoma of the breast

- Stage IV disease

- Stable disease for ≥ 28 days

- Measurable or evaluable disease OR no evidence of disease

- Not eligible for potentially curative therapy

- Adequately treated CNS metastases are allowed

- Hormone receptor status:

- Not specified

- HER-2/neu status:

- Not specified

PATIENT CHARACTERISTICS:

Age

- 18 and over

Sex

- Female

Menopausal status

- Not specified

Performance status

- ECOG 0-1

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count > 1,000/mm^3

- Platelet count > 100,000/mm^3

Hepatic

- Bilirubin ≤ 2. 0 mg/dL (unless due to Gilbert's syndrome)

- AST and ALT ≤ 2 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 5 times ULN

Renal

- Creatinine < 2. 0 mg/dL

Cardiovascular

- Ejection fraction ≥ 45% by echocardiogram or MUGA

Pulmonary

- Asthma or chronic obstructive pulmonary disease allowed provided daily systemic

corticosteroid therapy is not required

Immunologic

- No active autoimmune disease requiring systemic immunosuppressive therapy, including

any of the following:

- Inflammatory bowel disease

- Systemic vasculitis

- Scleroderma

- Psoriasis

- Multiple sclerosis

- Hemolytic anemia

- Immune-mediated thrombocytopenia

- Rheumatoid arthritis

- Systemic lupus erythematosus

- Sjögren's syndrome

- Sarcoidosis

- Other rheumatologic disease

- HIV negative

- No active acute or chronic infection

- No allergy to corn

Other

- No other malignancy within the past 5 years except carcinoma in situ of the cervix,

superficial nonmelanoma skin cancer, or superficial bladder cancer

- No active major medical or psychosocial problem that would preclude study

participation

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after study

participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

- More than 28 days since prior biologic therapy

- No other concurrent biologic therapy, including trastuzumab (Herceptin®)

Chemotherapy

- Prior adjuvant chemotherapy allowed

- Prior doxorubicin and cyclophosphamide allowed

- Prior doxorubicin dose combined with planned study therapy dose must not exceed a

lifetime cumulative dose of ≥ 450 mg/m^2

- More than 28 days since prior systemic chemotherapy

- No other concurrent systemic chemotherapy

Endocrine therapy

- More than 28 days since prior systemic corticosteroids

- Concurrent hormonal or endocrine therapy allowed

- No concurrent systemic corticosteroids

Radiotherapy

- More than 28 days since prior radiotherapy

- No concurrent radiotherapy

Surgery

- Not specified

Other

- More than 28 days since prior participation in another investigational drug trial

- No other concurrent investigational drugs

- Concurrent bisphosphonates allowed

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231-2410, United States; Recruiting
Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce, Phone: 410-955-8804, Email: jhcccro@jhmi.edu

Clinical trial summary from the National Cancer Institute's PDQ® database

Starting date: January 2004
Last updated: February 10, 2009